|Treatments:||Radiation, Biologic therapy||Hospital:||University of Western Australia, Fremantle Hospital|
This phase II study involved 91 indolent non-Hodgkin’s lymphoma patients with a median patient age of 62 years; 60% were male.
Patients were treated with radiation therapy and the biologic therapy agent rituximab, which is an antibody that recognizes the CD20 protein and targets cancer cells to be killed by the immune system.
The most severe side effects were grade 4, including neutropenia and thrombocytopenia.
The median overall survival was 50 months.
One of the authors received support from the pharmaceutical company Roche.
Correspondence: Dr. Michael F. Leahy; email: Michael.Leahy@health.wa.gov.au